External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT07528352
Phase
PHASE1
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Epcoritamab
  • Glofitamab
  • External Beam Radiation Therapy
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Participant aged ≥ 18 years
  • Disease criteria:
  • Histologically confirmed large b-cell lymphoma (LBCL), including DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and…
  • Relapsed or refractory disease with at least 2 prior systemic therapies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →